Member Info for jint

Dipped

Following persistent questioning on testing at last year’s AGM, RM stated they will be utilising the Casanova assay for autoantibodies, however they refused to name the manufacturer.

Remember this admission was after we’d been informed that they would be carrying out several small company funded Phase2 trials.

At this point in time it hasn’t been confirmed the Casanova assay will be used for the proposed MV trial.

However it would make sense to drill down further, in readiness, to engage patients with autoantibodies before they even deteriorate to the MV stage.

Apparently the test is very cost effective and timely.

At the moment the important point I’m interested in is, has the Casanova assay test reach authorisation stage yet.

Thanks Brand,

Excellent find!

Manifesto,

Apologies for misinterpretation, hmm maybe but going by last year this time round will undoubtedly be a hotbed of uncomfortable fire for them.

Let’s hope they have something of substance to announce via RNS beforehand.

Manifesto,

Yes I am expecting a Q&A session to take place otherwise and they know it, the meeting could be constantly interrupted by pertinent questioning.

Last year was a prime example even though they’d announced there would be a Q&A session.

IMO, I would say in his favour, SS excels at chairing and maintaining orderly meetings, which is to everyone benefit.

Doc.D

Yes I will be interested in what SS has to say particularly in light of his recent upbeat RNS statements, however I will maintain healthy scepticism until statements turn into facts.

As for PM, foremost being a scientist it’s quite obvious AGM’s are not his comfort zone. 2022 looked uncomfortable for him, last year he performed reasonably well explaining the deep dive (back in his zone). As for being in attendance this time round I wouldn’t bet on it.

Doc.D

“Mark Parry-Billings, latterly Global Head of Drug Development at Chiesi Farmaceutici S.p.A ("Chiesi"), will succeed Simon following that meeting.”

In light of the above statement, I’m assuming SS will chair the AGM, perhaps with MB-P in the background

Continued from previous post:

“Synairgen will have no further obligations to finance the development of the programme candidates, but will continue to provide technical support for the licensing process”

Pmjh

Apart from agreed assistance, it appears SNG involvement with Pharmaxis is now very much a waiting game for LOXL2 partnering agreements.

“Under the revised terms, Pharmaxis will take on full operational responsibilities for the programme, including the ongoing Phase I trial of the LOXL2 inhibitor PXS-5382. As a result of the combined work in the collaboration, Pharmaxis is concurrently developing a second LOXL2 inhibitor PXS-5338 (also in Phase I) which will expand partnering opportunities across multiple fibrotic conditions.”

“The revised agreement fixes Synairgen's interest across all fibrotic indications at cira 17% of all partnering proceeds.”

Pmjh

It appears the SNG / Pharmaxis agreement from January 2019 RNS still stands as there’s been no update to state otherwise.

Richard Marsden, Chief Executive Officer of Synairgen, said: "The successful completion of the longer term toxicology studies completes the data set. Pharmaxis is now conducting a final series of scientific briefings to potential partners. In accordance with the amended collaboration agreement with Pharmaxis, Synairgen will receive circa 17% of any future net partnering proceeds from all fibrotic indications for the LOXL2 inhibitors. We are really pleased about this positive development and look forward to further updates from Pharmaxis."

“I'm invested to the tune of a now embarrassing amount I put into the placing at £1.75”

How comes when the placing offer to retail investors orly amounted to £7m @175p and was on a pro rata basis for the amount of holdings held prior to the placing?

The bulk of the placement went to II’s and at the time was apparently oversubscribed.

Spaceman

“At best, they've got just over 10 months plus however long it takes to consummate a sale,”

Whilst I remain confident the next few weeks will yield plans and funding partner for the proposed MV trial, the BoD will be well aware that time is not on their side for the granted ILI patent expiration.

Whilst the granted ILI patent can be extended via ‘Exclusivity’ or ‘SPC’ application, it relies on SNG001 being authorised, from September they have 4years 7months remaining.

Therefore imo SNG at this late stage require a collaborative deal when taking into consideration the required time both Phase2 and Phase3 trials will take to complete.

Doable but they require a partner with clout.

Tommoclarke,

You and probably a number of the general public may have taken that view, however I’m sure public health authorities and the scientific communities don’t have such a laissez-faire attitude.

One word says it all really ‘UNIVERSAL’ or has TW dropped that too along with SNG’s involvement.

“TW is a contractor SNG no longer satisfy the retainer, monetary or technically”

A strange view, there’s more skin in the relationship than is suggested.

The two latest SNG patent applications were later amended to include TW as one of the named co-inventors in recognition of his work.

That work goes on, maybe the intensity is less but still bubbles away in the background. Don’t be surprised if there’s a development IP wise for secondary bacterial infections.

Bobfraeberks,

Good to see you’re still firing on all six SNG cylinders, topping up this week could be your opportune moment as I too remain comfortable that by Friday we’ll be happily surprised.

Penalty, robbed, on the bright side at least you’ll be back in time for the AGM 😀 and a beer.

“You have absolutely no knowledge of what TFG are doing in relation to SNG. Like us they will have expected a H1 trial date and no doubt sight of our final accounts by now... They may have been supportive at the AGM last year, but we have nothing but speculation to go on about their current views..”

Exactly and until such time an update appears I concur with TommyD’s wider view of the present situation, let’s wait and see, only 2weeks to go now.

“Really don't understand why or how Tommy can defend the position of the company.”

TommyD has answered in detail on numerous occasions to posters of all views with a pragmatic approach to the present situation.

IMO it’s apparent there are those whose intent and interest

are not conducive to the majority of PI’s who visit this BB.

If there are no ulterior motives at play, why are the negative posts beginning to reach numerical fever pitch when all will be revealed in approximately 2weeks, positive or negative.

Until such time the BoD retains my confidence and approval.

Just for the record the vibrating mesh nebuliser didn’t enter the market until the 90’s.

The wager is a con trick, play on devices, never mind effectiveness and efficiency, that doesn’t matter a hoot with tricky Sukura7.

Fruitznveg

Don’t rise to the shenanigans being played out here with spurious wagers from a suspect poster.

Sukura7

I suspect you are fully aware there are 3 main types of nebuliser.

The vibrating mesh nebuliser being the most effective and efficient, the very one that is employed for administering SNG001 formula.

If we are take you at face value, then the nebulisers you claim to have used would have been either ‘Jet’ or ‘Ultrasonic’, and certainly not in the same class as the ‘Aerogen’ nebuliser.

Little wonder your results back in the day were somewhat inconclusive using an inferior delivery product along with an unsuitable INF formula for adequate respiratory penetration.